Cognition Therapeutics Overview

  • Founded
  • 2007
Founded
  • Status
  • Private
  • Employees
  • 27
Employees
  • Latest Deal Type
  • Grant
  • Latest Deal Amount
  • $80M
Latest Deal Amount
  • Investors
  • 31

Cognition Therapeutics General Information

Description

Developer of small molecule drugs designed to treat people with central nervous system disorders like Alzheimer's disease, dementia with Lewy bodies (DLB), and Parkinson's disease. The company's drug candidates target the sigma-2 receptor complex, a key protein regulator, which prevents the binding of toxic proteins to their synaptic receptors thereby preserving brain health, enabling physicians to treat CNS diseases such as Alzheimer's and Parkinson's.

Contact Information

Website
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Primary Office
  • 2403 Sidney Street
  • Pittsburgh, PA 15203
  • United States
+1 (412) 000-0000

Cognition Therapeutics Timeline

2018201920202021
Financing RoundFinancing RoundCaptured Employee CountEstimated Employee Growth
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Cognition Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
19. Grant 08-Jun-2020 $80M 000.00 Completed Clinical Trials - Phase 2
18. Debt - PPP 11-Apr-2020 000.00 Completed Clinical Trials - Phase 2
17. Later Stage VC 31-Mar-2020 000.00 Completed Clinical Trials - Phase 2
16. Grant 21-Jun-2019 00.00 000.00 Completed Clinical Trials - Phase 2
15. Later Stage VC 27-Nov-2018 00.000 000.00 Completed Clinical Trials - Phase 2
14. Grant 08-Sep-2018 000.00 000.00 Completed Clinical Trials - Phase 2
13. Grant 16-Apr-2018 00.000 000.00 Completed Clinical Trials - Phase 2
12. Grant 18-Sep-2017 00.000 000.00 Completed Clinical Trials - Phase 2
11. Later Stage VC (Series B) 30-Nov-2016 $6.5M $24.6M 0000 Completed Clinical Trials - General
10. Grant 29-Sep-2016 $24.6M Completed Clinical Trials - General
To view Cognition Therapeutics’s complete valuation and funding history, request access »

Cognition Therapeutics Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series B 00,000,000 00.000000 00 00.00 00.00 00 00.00 00.000
Series A2 0,000,000 00.000000 00 00.00 00.00 00 00.00 0.000
Series A1 3,970,776 $0.001000 8% $0.69 $0.69 1x $0.69 9.86%
Series A 3,067,519 $0.001000 8% $0.69 $0.69 1x $0.69 7.62%
To view Cognition Therapeutics’s complete cap table history, request access »

Cognition Therapeutics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Developer of small molecule drugs designed to treat people with central nervous system disorders like Alzheimer's diseas
Drug Discovery
Pittsburgh, PA
27 As of 2020
000.00
0000000000 000.00

000000 0

lamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in vol
0000 000000000
Cambridge, MA
00 As of 0000
000.00
0000 0000-00-00
000000&0 000.00

00000000

agna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex e
0000000000000
Cambridge, MA
00 As of 0000
00000
0000 0000-00-00
00000000000 00000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Cognition Therapeutics Competitors (50)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Cadent Therapeutics Venture Capital-Backed Cambridge, MA 00 000.00 000000&0 000.00
00000000 000000000 Venture Capital-Backed Cambridge, MA 00 00000 00000000000 00000
0000 000000 Formerly VC-backed San Diego, CA 00 00000 00000000 00000
000 000000 Venture Capital-Backed Boston, MA 0 000.00 0000000000 0 000.00
0000000 Venture Capital-Backed Framingham, MA 00 0000 0000000000 0000
You’re viewing 5 of 50 competitors. Get the full list »

Cognition Therapeutics Executive Team (10)

Name Title Board Seat Contact Info
James O'Brien Chief Financial Officer
Susan Catalano Ph.D Co-Founder, Chief Scientific Officer & Board Member
Kenneth Moch Advisor
Anthony Caggiano MD Chief Medical Officer
Lisa Ricciardi Chief Executive Officer, President & Board Member
You’re viewing 5 of 10 executive team members. Get the full list »

Cognition Therapeutics Board Members (13)

Name Representing Role Since
Aaron Fletcher Ph.D Bios Partners Board Member 000 0000
Brett Monia Ph.D Self Board Member 000 0000
Irwin Scher MD Self Board Member 000 0000
Jack Khattar Self Board Member 000 0000
Mark Breedlove Self Board Member 000 0000
You’re viewing 5 of 13 board members. Get the full list »

Cognition Therapeutics Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Cognition Therapeutics Investors (31)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Atlanta Technology Angels Angel Group Minority 000 0000 000000 0
Audrey's Kitchen Family Office 000 0000 000000 0
Next Act Fund Angel Group 000 0000 000000 0
National Institute On Aging Government 000 0000 000000 0
Sofia Fund Angel Group Minority 000 0000 000000 0
You’re viewing 5 of 31 investors. Get the full list »